ArticleJHLT open2026

Intermediate-term risk of cardiac allograft vasculopathy following heart transplantation from hepatitis C viremic donors in the era of direct-acting antiviral therapy.

K Paternostro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.